Logo image of RCOR

RENOVACOR INC (RCOR) Stock Fundamental Analysis

NYSEARCA:RCOR - NYSE Arca - US75989E1064 - Common Stock - Currency: USD

3.2  +0.15 (+4.92%)

After market: 3.2 0 (0%)

Fundamental Rating

2

Overall RCOR gets a fundamental rating of 2 out of 10. We evaluated RCOR against 571 industry peers in the Biotechnology industry. While RCOR seems to be doing ok healthwise, there are quite some concerns on its profitability. RCOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year RCOR has reported negative net income.
RCOR had a negative operating cash flow in the past year.
RCOR Yearly Net Income VS EBIT VS OCF VS FCFRCOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -5M -10M -15M

1.2 Ratios

RCOR's Return On Assets of -22.84% is fine compared to the rest of the industry. RCOR outperforms 79.44% of its industry peers.
Industry RankSector Rank
ROA -22.84%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RCOR Yearly ROA, ROE, ROICRCOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 20 -20 40 60 80

1.3 Margins

RCOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCOR Yearly Profit, Operating, Gross MarginsRCOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021

6

2. Health

2.1 Basic Checks

The number of shares outstanding for RCOR has been increased compared to 1 year ago.
RCOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RCOR Yearly Shares OutstandingRCOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 5M 10M 15M
RCOR Yearly Total Debt VS Total AssetsRCOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

RCOR has an Altman-Z score of 0.24. This is a bad value and indicates that RCOR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.24, RCOR perfoms like the industry average, outperforming 55.61% of the companies in the same industry.
RCOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.24
ROIC/WACCN/A
WACCN/A
RCOR Yearly LT Debt VS Equity VS FCFRCOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 6.60 indicates that RCOR has no problem at all paying its short term obligations.
RCOR has a Current ratio of 6.60. This is comparable to the rest of the industry: RCOR outperforms 54.52% of its industry peers.
RCOR has a Quick Ratio of 6.60. This indicates that RCOR is financially healthy and has no problem in meeting its short term obligations.
RCOR's Quick ratio of 6.60 is in line compared to the rest of the industry. RCOR outperforms 54.52% of its industry peers.
Industry RankSector Rank
Current Ratio 6.6
Quick Ratio 6.6
RCOR Yearly Current Assets VS Current LiabilitesRCOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 20M 40M 60M 80M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.69% over the past year.
EPS 1Y (TTM)48.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RCOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y41.9%
EPS Next 2Y-18.1%
EPS Next 3Y-5.65%
EPS Next 5Y12.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RCOR Yearly Revenue VS EstimatesRCOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026
RCOR Yearly EPS VS EstimatesRCOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

0

4. Valuation

4.1 Price/Earnings Ratio

RCOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCOR Price Earnings VS Forward Price EarningsRCOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCOR Per share dataRCOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

RCOR's earnings are expected to decrease with -5.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.1%
EPS Next 3Y-5.65%

0

5. Dividend

5.1 Amount

RCOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RENOVACOR INC

NYSEARCA:RCOR (11/30/2022, 8:04:02 PM)

After market: 3.2 0 (0%)

3.2

+0.15 (+4.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-30 2022-11-30/amc
Earnings (Next)03-22 2023-03-22
Inst Owners36.04%
Inst Owner Change-15.94%
Ins Owners8.12%
Ins Owner Change0%
Market Cap55.26M
Analysts74.55
Price Target7.13 (122.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.13%
Min EPS beat(2)-62.16%
Max EPS beat(2)62.42%
EPS beat(4)2
Avg EPS beat(4)36.32%
Min EPS beat(4)-62.16%
Max EPS beat(4)190.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)-7.69%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0
BVpS2.47
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.6
Quick Ratio 6.6
Altman-Z 0.24
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.11%
EPS Next Y41.9%
EPS Next 2Y-18.1%
EPS Next 3Y-5.65%
EPS Next 5Y12.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-224.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3194.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3190.2%
OCF growth 3YN/A
OCF growth 5YN/A